FDA Grants Priority Review to Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
April 12th 2021Based on results of the phase 2 innovaTV 204 trial, the FDA granted priority review to tisotumab vedotin as a potential therapy for patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
New Guidance for Testing of Minimal Abnormalities Detected in Cervical Cancer Screening
October 18th 2020Following the new ASCCP-led national consensus guidelines for managing abnormal cervical cancer screening tests, these new guidelines estimate risk based on an individual’s risk factors, thus allowing for more personalized care management.
Balstilimab Monotherapy, Combination Shows Promise in Recurrent/Metastatic Cervical Cancer
September 25th 2020Balstilimab as a single agent and combined with zalifrelimab demonstrated promising objective response rates, regardless of PD-L1 expression, and a tolerable safety profile in patients with recurrent or metastatic cervical cancer.
Study Sees Encouraging Responses with Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer
September 24th 2020“Results from this study suggest that tisotumab vedotin has the potential to be a new therapy for patients with previously treated recurrent and/or metastatic cervical cancer,” said lead study author Robert L. Coleman, MD, FACOG, FACS.
Julie Torode Discusses the WHO Cervical Cancer Elimination Strategy
August 24th 2020The director of special projects at the Union for International Cancer Control spoke about the strategy released by the World Health Organization and what needs to occur to achieve the goals laid out by the organization.
HPV Vaccine Not Linked to Serious Complications in Adult Women
October 22nd 2017A large cohort study found no concerning safety issues associated with the use of human papillomavirus (HPV) vaccine in adult women. There was an increased rate of celiac disease, but this may be related to general underdiagnosis of the condition and its unmasking at vaccination visits.
USPSTF Proposes New Guidelines for Cervical Cancer Screening
October 11th 2017The USPSTF issued a new draft recommendation for cervical cancer screening, recommending screening with cervical cytology every 3 years for women aged 21 to 29, and offering a choice between cytology every 3 years and high-risk human papillomavirus testing every 5 years for those aged 30 to 65 years.